Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.

Lu W, Zhang C, Yi Z, Li Z, Wu Z, Fang YR. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia. J Mol Neurosci. 2012;47(3):505-10. DOI: 10.1007/s12031-012-9750-4. PubMed PMID: 22477643.

Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia.

Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2003;8(6):592-610. DOI: 10.1038/sj.mp.4001308. PubMed PMID: 12851636.

Neurotrophic factors and the pathophysiology of schizophrenic psychoses.

Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. European Psychiatry. 2004;19(6):326-37. DOI: 10.1016/j.eurpsy.2004.06.020. PubMed PMID: 15363470.

Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.

Lee B-H, Kim Y-K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology. 2009;59(1):51-8. DOI: 10.1159/000205518. PubMed PMID: 19270464.

Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment.

Ajami A, Hosseini SH, Taghipour M, Khalilian A. Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment. Scand J Immunol. 2014;80(1):36-42. DOI: 10.1111/sji.12158. PubMed PMID: 24498860.

Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.

Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007;22(1):21-7. DOI: 10.1097/YIC.0b013e3280103593. PubMed PMID: 17159456.

Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment.

Lee AH, Lange C, Ricken R, Hellweg R, Lang UE. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol. 2011;31(3):334-6. DOI: 10.1097/JCP.0b013e31821895c1. PubMed PMID: 21508862.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608. DOI: 10.1016/j.biopsych.2004.12.006. PubMed PMID: 15780846.

Cannabidiol monotherapy for treatment-resistant schizophrenia.

Zuardi AW, Hallak JEC, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-6. DOI: 10.1177/0269881106060967. PubMed PMID: 16401651.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271-80. PubMed PMID: 18833429.